Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact
Interacts (via the C-terminus 4300-4400 AA) with ATN1 (PubMed:19131340). Interacts with RERE (PubMed:19131340)
Expressed in many epithelial and some endothelial and smooth muscle cells
A PTB-like motif (DNXYH sequence) is required for the targeting to the leading edge. This motif represents a minimal protein-protein interaction core motif that is not regulated by tyrosine phosphorylation (By similarity)
| Cancer Type | Mutation Percentage |
|---|---|
| Central Nervous System Astrocytoma Grade Iv | 1.23% |
| Lung Adenocarcinoma | 8.12% |
| Lung Small Cell Carcinoma | 7.72% |
| Lung Squamous Cell Carcinoma | 8.84% |
| Oesophagus Adenocarcinoma | 1.55% |
| Oesophagus Squamous Cell Carcinoma | 11.14% |
| Pancreas Ductal Carcinoma | 1.87% |
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to FAT1, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 12
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT05873686 | Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma, Non-Small Cell Squamous Lung Cancer, Non-small Cell Lung Adenocarcinoma | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | PHASE1 | RECRUITING |
| NCT07030257 | Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | PHASE1, PHASE2 | RECRUITING |
| NCT02953093 | Aging | Study of Acarbose in Longevity | PHASE2 | TERMINATED |
| NCT06539091 | Epithelial Ovarian Cancer, Efficacy, Safety, Bone Mineral Density, Tolerability | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | PHASE3 | NOT_YET_RECRUITING |